Arsenic Disulfide Promoted Hypomethylation by Increasing DNA Methyltransferases Expression in Myelodysplastic Syndrome
Arsenic Disulfide Promoted Hypomethylation by Increasing DNA Methyltransferases Expression in Myelodysplastic Syndrome
复制标题
二硫化砷通过增加骨髓增生异常综合征中 DNA 甲基转移酶的表达促进低甲基化
DOI:
10.2147/dddt.s239158
复制
发表时间:
2020-04
期刊:
影响因子:
--
通讯作者:
Hu Xiao-Mei
中科院分区:
文献类型:
--
作者:
Zhou Qing-Bing;Liu Zheng-Tang;Wang Hong-Zhi;Guo Xiao-Qing;Xu Yong-Gang;Hu Xiao-Mei
Background Previous studies have shown that DNA methylation plays a significant role in myelodysplastic syndrome (MDS). In addition to hypermethylation, aberrant hypomethylation can result in the transcriptional activation of oncogenes in cancer, including MDS. Therefore, drugs targeting DNA hypomethylation are needed for the treatment of MDS. This study aimed to investigate whether As2S2 promoted hypomethylation by increasing DNA methyltransferases (DNMTs) expression in MDS. Patients and Methods Ten bone marrow samples from MDS patients and 3 healthy donors were obtained for the examination of the DNA methylation with a Human Methylation 850K BeadChip. The mRNA expressions for the DNMTs in the ten MDS patients and 3 controls were compared by Q-PCR. Then, the MDS cell line SKM-1 was treated with As2S2. After 2 days of treatment, Human Methylation 850K BeadChip was applied to analyze the changes of gene methylation status in the cells. Q-PCR and Western blot were taken to test the changes of mRNA and protein expressions for DNMTs in SKM-1 cells after treatment. Results Five hundred ninety-two abnormally hypomethylated genes were found in MDS patients compared to those in controls by Human Methylation 850K. The mRNA expressions of DNMTs (DNMT1, DNMT3a and DNMT3b) in MDS patients were significantly lower than those in healthy individuals. The IC50 value of As2S2 for SKM-1 cells was 4.97 μmol/L.Treatment with As2S2 at 2 μmoL/L resulted in significant alterations in the methylation levels at 1718 sites in SKM-1 cells compared to those in the controls. Hypermethylation was observed in 1625 sites (94.58%), corresponding to 975 genes, compared to those in the controls. Finally, the expression levels of DNMTs (DNMT1, DNMT3a, and DNMT3b) significantly increased in SKM-1 cells treated with As2S2 at 2 μmoL/L and 4 μmoL/L. Conclusion These data show a potential clinical application of As2S2 as an innovative hypermethylation agent in MDS.
登录
查看更多内容
影响因子:
20.3
作者:
Vardiman, James W.;Thiele, Juergen;Bloomfield, Clara D.
通讯作者:
Bloomfield, Clara D.
影响因子:
9
作者:
Zorea J;Prasad M;Cohen L;Li N;Schefzik R;Ghosh S;Rotblat B;Brors B;Elkabets M
通讯作者:
Elkabets M
DOI:
10.2147/dddt.s34271
发表时间:
2012
期刊:
Drug design, development and therapy
影响因子:
--
作者:
Cai Z;Bresell A;Steinberg MH;Silberg DG;Furlong ST
通讯作者:
Furlong ST
影响因子:
64.8
作者:
Wu, HJ;Chen, YP;Shang, YF
通讯作者:
Shang, YF
影响因子:
8.8
作者:
Wang X;Zhu Q;Lin Y;Wu L;Wu X;Wang K;He Q;Xu C;Wan X;Wang X
通讯作者:
Wang X